BCDA — BioCardia, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 925741 ·
Last close
$0.79
Market Cap
$11.93M
52W High
$1.80
52W Low
$0.66
ADV30
117,206
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -1,835,000 | -1,817,000 | 3,071,000 | 2,224,000 | 2,236,000 |
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 0 | — | -2,266,000 | -2,259,000 | 1,712,000 | 951,000 | 2,778,000 |
| Dec 2025 | 0 | — | -2,013,000 | -1,984,000 | 3,413,000 | 2,496,000 | 2,518,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-7,477,000
Investing CF
$-10,000
Financing CF
$7,489,000
CapEx
$-9,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.98
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-170,608,000
Inventory
—
Receivables
$20,000
ST Investments
—
EBIT TTM
$-7,818,000
Pretax Income TTM
$-7,775,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -8,278,000 | -8,228,000 | 3,413,000 | 2,518,000 | 895,000 | -7,436,000 |
| Dec 2024 | 58,000 | -8,001,000 | -7,946,000 | 3,724,000 | 2,887,000 | 837,000 | -7,886,000 |
| Dec 2023 | 477,000 | -11,644,000 | -11,571,000 | 2,987,000 | 4,590,000 | -1,603,000 | -9,974,000 |
| Dec 2022 | 1,352,000 | -11,901,000 | -11,907,000 | 9,793,000 | 4,901,000 | 4,892,000 | -10,561,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$4,005,000
NetIncome TTM
$-7,339,000
OpCashFlow TTM
—
Assets (Latest)
$4,755,000
Forward EPS
$-0.48
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ATYR | aTYR PHARMA INC | $12.47M | $4.99 | — |
| DYAI | DYADIC INTERNATIONAL INC | $12.66M | $0.32 | — |
| GRML | Greenland Mines Ltd | $10.87M | $3.42 | — |
| PASG | Passage BIO, Inc. | $13.58M | $4.22 | — |
| PLUR | Pluri Inc. | $14.09M | $0.98 | — |
News headlines (Yahoo Finance, 1h cache)
BioCardia (BCDA) Upgraded to Buy: Here's What You Should Know
2026-11-17 16:00 · Yahoo
BioCardia, Inc. Q3 2026 Earnings Call Summary
2026-11-13 13:30 · Yahoo
BioCardia (BCDA) Q3 2026 Earnings Call Transcript
2026-11-13 05:43 · Yahoo
BioCardia Inc (BCDA) (Q3 2026) Earnings Call Highlights: Japan Shonin Submission Advances as ...
2026-11-13 05:05 · Yahoo
BioCardia Reports Third Quarter 2026 Business Highlights and Financial Results
2026-11-12 21:19 · Yahoo
BioCardia to Host Q3 2026 Financial Results and Corporate Update Conference Call on November 12, 2026
2026-11-09 21:18 · Yahoo
BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval Application
2026-11-06 13:30 · Yahoo
BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter
2026-10-19 13:15 · Yahoo
BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting
2026-10-07 13:00 · Yahoo
BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter
2026-10-01 13:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.